Positive safety results reported for Nyxol in pediatric patients

Nyxol demonstrated positive results in a pediatric safety trial to reverse pharmacologically induced mydriasis, according to a press release from Ocuphire Pharma.
Safety and efficacy results in the subjects aged 3 to 11 years in the MIRA-4 trial were consistent with those seen in previous studies conducted in both teenagers and adults.
“These results add to our large body of clinical data demonstrating the safety and efficacy of Nyxol for [pharmacologically induced mydriasis] and may potentially support a broader label to include children as young as age 3 to older adults,” Ocuphire

Nyxol demonstrated positive results in a pediatric safety trial to reverse pharmacologically induced mydriasis, according to a press release from Ocuphire Pharma.
Safety and efficacy results in the subjects aged 3 to 11 years in the MIRA-4 trial were consistent with those seen in previous studies conducted in both teenagers and adults.
“These results add to our large body of clinical data demonstrating the safety and efficacy of Nyxol for [pharmacologically induced mydriasis] and may potentially support a broader label to include children as young as age 3 to older adults,” Ocuphire